China NMPA Medical Device Registration Consultant

Scope and evidence must be confirmed before any paid tests or filings.

A China NMPA medical device registration consultant should resolve the regulatory route before anyone commissions testing or assembles a submission. The first deliverable is a documented classification hypothesis, evidence-gap map and decision on what must be verified—not a promise of approval. These rules concern mainland China; the exact product, intended use and manufacturing arrangement determine the result.

1. Define the product before selecting the route

A foreign approval code or a marketing label is not a Chinese classification. Start with the intended medical purpose and the applicable Chinese classification rules and catalogue. A borderline or novel product may require a formal classification inquiry; do not infer Class I merely because it is low-risk elsewhere. For an in-vitro diagnostic (IVD) reagent, check the separate IVD provisions under SAMR Order No. 48 rather than applying the general-device rules mechanically.

Intended use, patient population, indications and any diagnostic or therapeutic claims.
Technology: invasiveness, duration of contact, energy source, software/AI functions, materials and accessories.
Product family: model variants, components, kits and whether one registration unit is justified.
Applicant and manufacturing facts: legal manufacturer, production location, China-import status and existing approvals.

Decision gate: write down the proposed China category, closest catalogue entry and unresolved differences. If the product does not clearly match, obtain a classification position before locking the test plan or a commercial launch date.

2. Choose filing or registration—and the competent authority

The distinction between import and domestic manufacture affects the authority. Under SAMR Order No. 47, Class I uses filing; Classes II and III use registration. The following is a route map, not a classification of a specific device.

Origin / class	I	II	III
Imported device	Filing — NMPA	Registration — NMPA	Registration — NMPA
Domestically manufactured device	Filing — competent city-level drug regulator	Registration — competent provincial drug regulator	Registration — NMPA

For an overseas brand manufacturing in mainland China, do not automatically use the import column: the actual applicant/manufacturer arrangement matters. Confirm the specific registration unit and whether a device has already been approved or reclassified before applying these branches.

For a device made in mainland China by an overseas company, NMPA’s 2021 implementation notice specifies that the domestic manufacturing enterprise acts as registration or filing applicant. A separate 2025 NMPA policy (Announcement No. 30) concerns eligible domestic production of already-registered imported Class II/III devices through certain foreign-invested enterprises, including those under the same actual controller. It does not automatically turn an imported certificate into a domestic one: verify the existing imported certificate, corporate-control evidence, applicant authorization, production changes, dossier-reuse limits and QMS comparability before selecting that path.

3. Use an evidence-gap matrix to decide what to do first

Ask the consultant to return an evidence register with source files, applicability, missing proof, owner and a hold/release decision for each workstream. The following four gates prevent premature testing or filing.

Decision gate	Evidence to compare	If the gap remains
Classification and scope	Chinese catalogue entry vs intended purpose, risk, models and product boundaries.	Hold the route; resolve classification or split the product scope.
Product technical requirements and testing	Draft China product technical requirements (PTR), applicable mandatory standards, test methods, representative samples and available reports.	Do not order tests against an unstable PTR; assess accepted self-testing or qualified external testing under applicable rules.
Clinical justification	Eligibility for a clinical-evaluation exemption; otherwise published/previous clinical data, predicate comparability, access rights and unresolved differences.	Prepare a substantiated evaluation route; where evidence is insufficient, determine whether a clinical trial is necessary.
Applicant and dossier integrity	Applicant identity, China agent, overseas marketing documents where applicable, Chinese-language materials and QMS traceability.	Fix responsibility or documentary conflicts before submission; a consultant is not automatically the statutory agent.

A gap is not necessarily a requirement for new tests: classify it as “reusable with explanation”, “adapt”, “generate” or “regulatory clarification needed”. Record the basis for each choice.

4. Reuse overseas evidence conditionally, not automatically

CE marking, an FDA decision and ISO certificates can support a dossier, but they do not substitute for the China classification and application. Map every foreign report to the Chinese intended use, exact model, version, PTR indicator, relevant standard and test method. Record deviations and who has rights to underlying clinical or technical data.

SAMR Order No. 47 permits either applicant self-test reports or reports from qualified entrusted testing institutions, subject to the applicable self-test and product requirements. “Every product must be tested in China” is therefore too broad; “any foreign report is accepted” is also unsafe. Decide test strategy only after assessing competence, sample representativeness, methods and the Chinese PTR.

Clinical evaluation and a clinical trial are different decisions. Order No. 47 provides defined circumstances for exemption from clinical evaluation, and existing literature or comparable-device data may support an evaluation; inadequate evidence can trigger a trial. NMPA’s implementation notice also states that Class I filing does not require submission of clinical-evaluation data. Do not confuse exemption from clinical evaluation with exemption from all safety/performance evidence.

5. Sequence the project through four approval gates

Freeze the China intended use and device/IVD boundary; list models, production sites and claims that could alter the category.
Confirm the classification and import/domestic branch; record any unresolved regulatory interpretation or authority clarification.
Approve the PTR/standards and clinical-evidence strategy after the gap review; only then commission missing tests or studies.
Confirm applicant, Chinese agent, Chinese dossier and QMS document owners; authorize filing execution only when the critical gaps are closed.

The practical output is a decision memo with assumptions, dated evidence, alternative routes, stop conditions and the next accountable action—not an invented fixed fee, timetable or guaranteed registration outcome.

Date-sensitive QMS checkpoint: NMPA’s revised Good Manufacturing Practice for Medical Devices was issued in 2025 but takes effect on 1 November 2026. When preparing a project that will extend beyond that date, assess the transition and implementation requirements for the relevant manufacturer; do not treat the revised GMP as already effective on 15 October 2026.

6. Separate advisory advice from representation and filing

For overseas applicants, Order No. 47 requires appointment of an enterprise legal person in China as agent; this is a statutory role, not merely a translation or consulting assignment. The overseas applicant remains responsible under the regulatory framework. Registration/filing materials are submitted in Chinese, with original foreign-language documents where translated. Imported-device marketing documentation is ordinarily required under Article 18, with specified exceptions, including the rule for qualifying innovative devices not yet marketed in the relevant home jurisdiction.

When classification and gaps are signed off, hand over the approved decision memo and evidence register to the execution team. Keep the route review separate from detailed dossier assembly, agency appointment and ongoing product surveillance. For a broader non-device classification problem, review the general China market-access route instead.

Official regulatory sources

Frequently asked strategic questions

Does EU CE marking or US FDA clearance decide the NMPA class?

No. These may provide reusable evidence, but class, registration unit and route must be assessed against the Chinese classification rules and current catalogue.

Can an imported Class I device be registered as Class II to be safe?

Do not choose a higher class as a shortcut. Imported Class I devices follow NMPA filing; imported Classes II and III follow NMPA registration. Resolve an uncertain classification first.

Is a China clinical trial always necessary for Class II or III?

No. First examine clinical-evaluation exemptions and the suitability of existing literature or comparable-device evidence. A trial may be needed when these cannot establish safety and effectiveness.

Are foreign test reports, or in-house tests, enough?

Not automatically. Check whether the report and testing route satisfy the Chinese PTR, standards, competence and representative-sample requirements; Order No. 47 expressly allows qualifying self-test reports.

Can an overseas manufacturer use its consultant as the China agent?

Only if the appointed entity qualifies for and actually accepts the statutory China-agent role. A strategy consultant is not automatically the appointed domestic enterprise legal person.

What if the product is an IVD reagent or combines multiple technologies?

First confirm the regulatory object and any applicable separate IVD regime under Order No. 48. Complex combinations may require classification clarification before choosing a device registration unit or studies.